HIGHLIGHTS
- who: Lingxiang Jiang from the University of Porto, Portugal France have published the article: KP372-1-Induced AKT Hyperactivation Blocks DNA Repair to Synergize With PARP Inhibitor Rucaparib via Inhibiting FOXO3a/GADD45u03b1, in the Journal: (JOURNAL)
- what: Antibodies used in this study for immunofluorescence and Western blotting were shown in Supplemental Material and Methods. The authors show that combining PARPi with KP372-1 leads to synergistic antitumor effect with non-toxic doses of both drugs in NQO1 overexpressing cancer cells. The authors show that KP372-1 combined with PARPi resulted in enhanced toxicity and synergistic . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.